{"doi":"10.1101/2024.03.04.583431","title":"Effects of access condition on substance use disorder-like phenotypes in male and female rats self-administering MDPV or cocaine","abstract":"Abstract Substance use disorder (SUD) is a heterogeneous disorder, where severity, symptoms, and patterns of substance use vary across individuals. Yet, when rats are allowed to self-administer drugs such as cocaine under short-access conditions, their behavior tends to be well-regulated and homogeneous in nature; though individual differences can emerge when rats are provided long– or intermittent-access to cocaine. In contrast to cocaine, significant individual differences emerge when rats are allowed to self-administer 3,4-methylenedioxypyrovalerone (MDPV), even under short-access conditions, wherein ∼30% of rats rapidly transition to high levels of drug-taking. This study assessed the SUD-like phenotypes of male and female Sprague Dawley rats self-administering MDPV (0.032 mg/kg/infusion) or cocaine (0.32 mg/kg/infusion) by comparing level of drug intake, responding during periods of signaled drug unavailability, and sensitivity to footshock punishment to test the hypotheses that: (1) under short-access conditions, rats that self-administer MDPV will exhibit a more robust SUD-like phenotype than rats that self-administered cocaine; (2) female rats will have a more severe phenotype than male rats; and (3) compared to short-access, long– and intermittent-access to MDPV or cocaine self-administration will result in a more robust SUD-like phenotype. After short-access, rats that self-administered MDPV exhibited a more severe phenotype than rats that self-administered cocaine. Though long– and intermittent-access to cocaine and MDPV self-administration altered drug-taking patterns, manipulating access conditions did not systematically alter their SUD-like phenotype. Evidence from behavioral and quantitative autoradiography studies suggest that these differences are unlikely due to changes in expression levels of dopamine transporter, dopamine D 2 or D 3 receptors, or 5-HT 1B , 5-HT 2A , or 5-HT 2C receptors, though these possibilities cannot be ruled out. These results show that the phenotype exhibited by rats self-administering MDPV differs from that observed for rats self-administering cocaine, and suggests that individuals that use MDPV and/or related cathinones may be at greater risk for developing a SUD, and that short-access MDPV self-administration may provide a useful method to understand the factors that mediate the transition to problematic or disordered substance use in humans.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2024,"id":488071,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9592,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1003146,"name":"Nina M. Beltran","orcid":null,"position":1,"is_corresponding":false},{"id":1310124,"name":"Mark S.A. Bushnell","orcid":null,"position":2,"is_corresponding":false},{"id":1277353,"name":"Maaz Syed","orcid":"0000-0003-0530-8306","position":3,"is_corresponding":false},{"id":1310125,"name":"Valeria Acosta","orcid":null,"position":4,"is_corresponding":false},{"id":1310126,"name":"M. Desai","orcid":null,"position":5,"is_corresponding":false},{"id":301852,"name":"Kenner C. Rice","orcid":"0000-0002-1147-9147","position":6,"is_corresponding":false},{"id":1002856,"name":"Katherine M. Serafine","orcid":"0000-0002-5099-8505","position":7,"is_corresponding":false},{"id":790819,"name":"Georgianna G. Gould","orcid":"0000-0002-5470-8763","position":8,"is_corresponding":false},{"id":451283,"name":"Lynette C. Daws","orcid":"0000-0002-6793-791X","position":9,"is_corresponding":false},{"id":415889,"name":"Gregory T. Collins","orcid":"0000-0002-2499-3356","position":10,"is_corresponding":false},{"id":415887,"name":"Michelle R. Doyle","orcid":"0000-0003-4303-2478","position":0,"is_corresponding":true}],"reference_count":94,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:08:15.008850Z","pmid":"38496609","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}